Company
Science
Team
Contact
Investor Relation
▼
Scheme of Arrangement
▼
MOA & AOA of both companies
▼
MOA
AOA
Accounting Treatment Certificate for Amalgamation
Audited Financial Statements (Last 3 Years)
▼
NKure Audit report FY 2022-23
NKure Audit report FY 2023-24
NKure Audit Report FY 2024-25
NKure Financials 2022-23
NKure Financials 2023-24
NKure Financials 2024-25
Notices & Orders
▼
Nkure- Notice to equity shareholders
Nkure- Notice to preference shareholders
NCLT Order
Company
Science
Team
Contact
Investor Relation
Scheme of Arrangement
MOA & AOA of both companies
MOA
AOA
Accounting Treatment Certificate for Amalgamation
Audited Financial Statements (Last 3 Years)
NKure Audit report FY 2022-23
NKure Audit report FY 2023-24
NKure Audit Report FY 2024-25
NKure Financials 2022-23
NKure Financials 2023-24
NKure Financials 2024-25
Notices & Orders
Nkure- Notice to equity shareholders
Nkure- Notice to preference shareholders
NCLT Order
×
Company
Science
Team
Contact
Investor Relation
Scheme of Arrangement
MOA & AOA of both companies
MOA
AOA
Accounting Treatment Certificate for Amalgamation
Audited Financial Statements (Last 3 Years)
NKure Audit report FY 2022-23
NKure Audit report FY 2023-24
NKure Audit Report FY 2024-25
NKure Financials 2022-23
NKure Financials 2023-24
NKure Financials 2024-25
Notices & Orders
Nkure- Notice to equity shareholders
Nkure- Notice to preference shareholders
NCLT Order
NKure – NK for a cure
A novel approach to creating affordable NK-cell based therapies
×
Signup
Error:
Contact form not found.
